Amid already plunging use of Merck’s Covid-19 antiviral Lagevrio, preprint gives look into real world performance
One day after the FDA granted Pfizer’s Paxlovid emergency use authorization in December, it did the same for Merck’s Covid-19 antiviral molnupiravir, marketed as Lagevrio — but only for cases in which other treatments were “not accessible or clinically appropriate.”
Fast forward 10 months. Far fewer patients have used Merck’s drug, according to the HHS tracker. As of Oct. 2, out of around 2.5 million doses of Lagrevio ordered, around 755,000 have been used. Compare that to 8 million doses of Paxlovid ordered and 5 million administered.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
